TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03779854

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Bone Marrow Transplantation
Description: Receive unmanipulated T cell replete BM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation
Description: Receive naive T-cell depleted PBSCs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo CSF and blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo CSF and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT02797873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AQ
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAS-20
Description: See Detailed Study Description.
Study: NCT03935750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament reconstruction (ACLR)
Description: All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cruciate ligament reconstruction (ACLR)
Description: All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament reconstruction (ACLR)
Description: All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cruciate ligament reconstruction (ACLR)
Description: All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral extra-articular tenodesis (LET)
Description: Participants randomized to the BPTB or QT arms will be randomized a second time to a LET procedure or no additional surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral extra-articular tenodesis (LET)
Description: Participants randomized to the BPTB or QT arms will be randomized a second time to a LET procedure or no additional surgery.
Study: NCT02370290

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Clinical and imaging information collected

Intervention type: OTHER
Intervention: Informational Intervention
Description: Clinical and imaging data collected
Study: NCT02631603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administer Placebo as anti-inflammatory

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Administer Prednisolone as anti-inflammatory
Study: NCT03122886

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat Emulsion
Description: Given IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study: NCT01677338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc sulfur colloid
Description: PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc sulfur colloid
Description: PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
Study: NCT02965209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: motorized spiral enteroscopy
Description: Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. When the region of interest in the small bowel is reached by NMSE standard endoscopic techniques, e.g. argon plasma coagulation (APC), forceps biopsy or endoscopic mucosal resection (EMR) are performed for treatment and/or tissue acquisition.
Study: NCT01167179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led consultation
Description: Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
Study: NCT00414869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX-1000
Description: 500 mg powder sachets to be taken as 1, 2, or 4 sachets twice daily, PO x 16 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive powder matching NCX-1000
Study: NCT03447379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 antagonist monotherapy
Description: P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin plus P2Y12 antagonist
Description: DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) for a year
Study: NCT03488108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil Foam
Description: Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil Foam
Description: Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.
Study: NCT02781506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SAbR
Description: SAbR (1-3 lesions)
Study: NCT00608361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00311155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
Description: Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
Study: NCT05683236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Doctors carried out health education for patients to avoid patients giving up their lives, encouraged them to actively cooperate with medical staff, and instructed patients on how to face the disease with a brave and strong attitude and actively fight the disease. Nurses conducted daily psychological counselling for patients, learnt their inner thoughts through communication with patients, and provided timely comfort and encouragement. An attention-shifting method can be used to alleviate the patient's attention to the disease, effectively improving internal depression and avoiding depression. For patients with anxiety and loneliness, family members were instructed to accompany and care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort care
Description: Reasonable control of indoor temperature and humidity is necessary to ensure that warm, light conditions permit properly dressed patients to feel warm. Nurses need to ensure that patients are kept clean and tidy in personal hygiene. They would regularly assist patients in turning over while giving patients sufficient respect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain care
Description: Clinicians should regularly evaluate the patient's physical pain and give reasonable analgesic drugs to patients. Nurses should closely observe the medication response of patients. At the same time, it is necessary to observe and record patients' physical pain daily and take effective pain control measures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary care
Description: The clinical nutritionist formulated appropriate nutritional diets according to the nutritional status and personal preferences of patients, provided nutritional support for patients, and followed up with patients once a week after discharge to improve their nutritional status.
Study: NCT03834662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVID200
Description: A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVID200
Description: A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVID200
Description: A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
Study: NCT01326637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Overview Document
Description: The Intervention has two components:~1. Pre-visit care coordination:~   * 5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~  * The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~2. Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD.
Study: NCT02725580

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AT-GTX-501
Description: CLN6 Gene delivered by Self-Complementary AAV9
Study: NCT01025141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skeletal anchorage (MINISCREW)
Description: Skeletal anchorage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental anchorage
Description: dental anchorage (reference)
Study: NCT02252016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazoprevir + Elbasvir
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
Study: NCT03328273

Intervention type: DRUG
Group type: OTHER
Intervention: Ceralasertib
Description: An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
Study: NCT05683236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological and social support care
Description: Two nurses with psychological counselling qualifications in the team used the anxiety and depression scale to evaluate the psychological and emotional status of patients and referred to The Questionnaire Survey on Awareness of Palliative Care by the Department of Elderly Section of the union medical college hospital. The content mainly included the patient's medical history and general situation, the needs and awareness of patients and their families for palliative care, the choice of patients and their families for the final treatment plan, and the needs of families for grief counselling. Timely professional counselling and intervention were undertaken to alleviate the patient's adverse emotions.
Study: NCT02252016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir + Elbasvir
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
Study: NCT05683236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine nursing intervention
Description: The control group was given routine nursing intervention, strictly in accordance with a routine treatment process, monitoring the vital signs of patients, giving basic nursing, health education, diet guidance and so on.
Study: NCT02252016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
Study: NCT01608646

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: S-1 plus oxaliplatin
Description: S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
Study: NCT02797873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAS-20
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raven's SPM
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raven's SPM
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading ability
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading ability
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ishihara's tests for colour deficiency
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ishihara's tests for colour deficiency
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional questionnaire
Description: including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional questionnaire
Description: including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown-ADD
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown-ADD
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MFQ
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MFQ
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAI-T
Description: See Detailed Study Description.
Study: NCT03328273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
Study: NCT01959945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok® Quadrivalent Influenza Virus Vaccine
Description: Intramuscular (Relevant year formulation)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok® Quadrivalent Influenza Virus Vaccine
Description: Intramuscular (Relevant year formulation)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Quadrivalent® Influenza Virus Vaccine
Description: Intramuscular (Relevant year formulation)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Quadrivalent® Influenza Virus Vaccine
Description: Intramuscular (Relevant year formulation)
Study: NCT01919463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal Compression
Description: Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal Compression
Description: Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
Study: NCT02797873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAI-T
Description: See Detailed Study Description.
Study: NCT01919463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guidance of Magnetic Endoscopic Imaging (MEI) System
Description: Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
Study: NCT02797873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIS
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIS
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAWBA
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAWBA
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAI-S
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAI-S
Description: See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleepiness rating
Description: Acquired 6 times while in MRI-scanner. See Detailed Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleepiness rating
Description: Acquired 6 times while in MRI-scanner. See Detailed Study Description.
Study: NCT02662907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barium Swallow
Description: Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Barium Swallow
Description: Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST) Device
Description: Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Manometer
Description: Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive Exams
Description: Participants given neurocognitive exams at baseline.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurocognitive Exams
Description: Participants given neurocognitive exams at baseline.
Study: NCT00931138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (Aracytine + Daunorubicin)
Description: Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3